Cargando…
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713042/ https://www.ncbi.nlm.nih.gov/pubmed/36467814 http://dx.doi.org/10.1002/jha2.517 |
_version_ | 1784841922818342912 |
---|---|
author | Zhu, Jun Hong, Xiaonan Song, Yu Qin Hodkinson, Brendan Balasubramanian, Sriram Wang, Songbai Zhang, Qingyuan Shi, Yuankai Huang, Huiqiang Zhang, Huilai Zhu, Yan Shreeve, Stephen Martin Sun, Steven Wang, Ze Wang, Xiaocan Fan, Yue Wilson, Wyndham Vermeulen, Jessica |
author_facet | Zhu, Jun Hong, Xiaonan Song, Yu Qin Hodkinson, Brendan Balasubramanian, Sriram Wang, Songbai Zhang, Qingyuan Shi, Yuankai Huang, Huiqiang Zhang, Huilai Zhu, Yan Shreeve, Stephen Martin Sun, Steven Wang, Ze Wang, Xiaocan Fan, Yue Wilson, Wyndham Vermeulen, Jessica |
author_sort | Zhu, Jun |
collection | PubMed |
description | In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in the intent‐to‐treat (ITT; n = 200, hazard ratio [HR] = 0.83, 95% confidence interval [CI]: 0·509–1.349; p = 0.4495) or activated B‐cell‐like (ABC; n = 141 [based on available gene‐expression profiling data], HR = 0.86, 95% CI: 0.467–1.570; p = 0.6160) subpopulations. However, ibrutinib+R‐CHOP improved EFS (HR = 0·50, 95% CI: 0.251–1.003) and progression‐free survival (PFS; HR = 0.48, 95% CI: 0.228–1.009) versus placebo+R‐CHOP in patients aged <60 but not ≥60 years. Grade ≥3 serious treatment‐emergent adverse events occurred more with ibrutinib+R‐CHOP (45·6% vs. 31·3%). The percentage of patients receiving ≥6 cycles of R‐CHOP was similar across treatment arms in those <60 years. A numerical trend was seen towards improved EFS and PFS with ibrutinib+R‐CHOP versus placebo+R‐CHOP in patients with MYC‐high/BCL2‐high co‐expression. In this slightly younger Chinese subgroup, ibrutinib+R‐CHOP did not improve EFS in the ITT and ABC subpopulations but improved outcomes with manageable safety in patients <60 years, consistent with overall PHOENIX study outcomes. |
format | Online Article Text |
id | pubmed-9713042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97130422022-12-02 Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial Zhu, Jun Hong, Xiaonan Song, Yu Qin Hodkinson, Brendan Balasubramanian, Sriram Wang, Songbai Zhang, Qingyuan Shi, Yuankai Huang, Huiqiang Zhang, Huilai Zhu, Yan Shreeve, Stephen Martin Sun, Steven Wang, Ze Wang, Xiaocan Fan, Yue Wilson, Wyndham Vermeulen, Jessica EJHaem Haematologic Malignancy ‐ Lymphoid In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in the intent‐to‐treat (ITT; n = 200, hazard ratio [HR] = 0.83, 95% confidence interval [CI]: 0·509–1.349; p = 0.4495) or activated B‐cell‐like (ABC; n = 141 [based on available gene‐expression profiling data], HR = 0.86, 95% CI: 0.467–1.570; p = 0.6160) subpopulations. However, ibrutinib+R‐CHOP improved EFS (HR = 0·50, 95% CI: 0.251–1.003) and progression‐free survival (PFS; HR = 0.48, 95% CI: 0.228–1.009) versus placebo+R‐CHOP in patients aged <60 but not ≥60 years. Grade ≥3 serious treatment‐emergent adverse events occurred more with ibrutinib+R‐CHOP (45·6% vs. 31·3%). The percentage of patients receiving ≥6 cycles of R‐CHOP was similar across treatment arms in those <60 years. A numerical trend was seen towards improved EFS and PFS with ibrutinib+R‐CHOP versus placebo+R‐CHOP in patients with MYC‐high/BCL2‐high co‐expression. In this slightly younger Chinese subgroup, ibrutinib+R‐CHOP did not improve EFS in the ITT and ABC subpopulations but improved outcomes with manageable safety in patients <60 years, consistent with overall PHOENIX study outcomes. John Wiley and Sons Inc. 2022-08-30 /pmc/articles/PMC9713042/ /pubmed/36467814 http://dx.doi.org/10.1002/jha2.517 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Haematologic Malignancy ‐ Lymphoid Zhu, Jun Hong, Xiaonan Song, Yu Qin Hodkinson, Brendan Balasubramanian, Sriram Wang, Songbai Zhang, Qingyuan Shi, Yuankai Huang, Huiqiang Zhang, Huilai Zhu, Yan Shreeve, Stephen Martin Sun, Steven Wang, Ze Wang, Xiaocan Fan, Yue Wilson, Wyndham Vermeulen, Jessica Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title_full | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title_fullStr | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title_full_unstemmed | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title_short | Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial |
title_sort | ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre b‐cell‐like diffuse large b‐cell lymphoma: a chinese subgroup analysis of the phase iii phoenix trial |
topic | Haematologic Malignancy ‐ Lymphoid |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713042/ https://www.ncbi.nlm.nih.gov/pubmed/36467814 http://dx.doi.org/10.1002/jha2.517 |
work_keys_str_mv | AT zhujun ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT hongxiaonan ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT songyuqin ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT hodkinsonbrendan ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT balasubramaniansriram ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT wangsongbai ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT zhangqingyuan ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT shiyuankai ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT huanghuiqiang ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT zhanghuilai ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT zhuyan ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT shreevestephenmartin ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT sunsteven ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT wangze ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT wangxiaocan ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT fanyue ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT wilsonwyndham ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial AT vermeulenjessica ibrutinibandrituximabpluscyclophosphamidedoxorubicinvincristineandprednisoneinpatientswithpreviouslyuntreatednongerminalcentrebcelllikediffuselargebcelllymphomaachinesesubgroupanalysisofthephaseiiiphoenixtrial |